Article Sidebar
Published:
Jun 23, 2016Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Association of Fibroblast Growth Factor (Fgf-21) as a Screening Biomarker for Chronic Progressive External Ophthalmoplesia
Abstract
Purpose: To investigate whether or not fibroblast growth factor (FGF-21) can be used as a screening biomarker in chronic progressive external ophthalmoplesia (CPEO) patients.
Methods: FGF-21 concentration was measured in the serum of 24 patients with CEPO phenotype and 24 control samples by enzyme-linked immunosorbent assay (ELISA) and determined the deletion of mitochondrial genome by multiplex polymerase chain reaction (PCR).
Results: FGF-21 concentration in 50 % of CPEO patients showed notable differences from that in control subjects. FGF-21 concentration ratio in patient group, 2 disorder control groups (mitochondrial and non-mitochondrial) and normal group, respectively, was 294.87 } 42.10 (p < 0.0001), 761.78} 75.07 (p < 0.0001), 124.26 } 12.27 (p = 0.1203), 69.27 } 10.09 (p = 0.2195). A statistically significant inverse correlation between FGF-21 concentration and age onset was found, with a significant difference (p < 0.05) in the age group . 19 years (mean FGF-21 concentration, 460.36 pg/mL) and for the age group . 51years (mean concentration FGF-21, 57.87 pg/mL. Surprisingly, there was no significant difference between FGF-21 concentration and age in the mid-age group (20 . 50 years) .
Conclusion: These findings indicate that FGF-21 concentration significantly increases in CPEO patients like in other mitochondrial disorders and this factor can be used as a biomarker in primary diagnosis of mitochondrial disorders. In this regard, FGF-21 assay is only valid in teenagers and the >
50 years age group who show acute symptoms.
Keywords: Chronic progressive external ophthalmoplesia, Fibroblast growth factor-21, Mitochondrial disorders, Ophthalmoplesia, Biomarker
